Fertility-preserving treatment in complex atypical hyperplasia and early endometrial cancer in young women with oral progestin: Is it effective?
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
ObjectiveThe aim of this study is to assess the effectiveness of oral progestin treatment in women diagnosed with complex atypical hyperplasia (CAH) or grade 1 endometrial cancer (G1EC), who desire to preserve their fertility, as alternative treatment to a hysterectomy. MethodsWe reviewed the medical records of women younger than 45 years old that had been diagnosed with CAH or G1EC, who expressed a desire to preserve their fertility using alternative treatment at our institution. Women without evidence of myometrial invasion on pelvic magnetic resonance imaging scans were included. The study period was between 2004 and 2014. Endometrial biopsies were taken at follow-up appointments. ResultsWe identified 31 young women with CAH or G1EC. The median age was 33 years old (range, 20 to 41), and the median period of time undertaking the treatment was 5 months (range, 1 to 12). Twenty-three patients (74.2%) achieved complete remission (CR; median time to CR was 3 months; range, 1 to 22), 16 patients (88.9%) with CAH and 7 (53.8%) with G1EC achieved CR. 6 patients (26.1%) who had achieved CR, had recurrence of the disease (median time from CR to recurrence was 12.5 months; range, 4 to 18). Eight patients (25.8%) finally underwent a hysterectomy. ConclusionOral progestin therapy is an alternative treatment for women with CAH or G1EC who desire fertility preservation. However, more prospective studies are needed for standard progestin regimen. Also, there still remains a risk of disease progression and recurrence. Therefore, close follow-up is important during treatment and after CR. In addition, a hysterectomy is recommended as a definitive treatment after completion of childbearing.
Abstract
ObjectiveThe aim of this study is to assess the effectiveness of oral progestin treatment in women diagnosed with complex atypical hyperplasia (CAH) or grade 1 endometrial cancer (G1EC), who desire to preserve their fertility, as alternative treatment to a hysterectomy. MethodsWe reviewed the medical records of women younger than 45 years old that had been diagnosed with CAH or G1EC, who expressed a desire to preserve their fertility using alternative treatment at our institution. Women without evidence of myometrial invasion on pelvic magnetic resonance imaging scans were included. The study period was between 2004 and 2014. Endometrial biopsies were taken at follow-up appointments. ResultsWe identified 31 young women with CAH or G1EC. The median age was 33 years old (range, 20 to 41), and the median period of time undertaking the treatment was 5 months (range, 1 to 12). Twenty-three patients (74.2%) achieved complete remission (CR; median time to CR was 3 months; range, 1 to 22), 16 patients (88.9%) with CAH and 7 (53.8%) with G1EC achieved CR. 6 patients (26.1%) who had achieved CR, had recurrence of the disease (median time from CR to recurrence was 12.5 months; range, 4 to 18). Eight patients (25.8%) finally underwent a hysterectomy. ConclusionOral progestin therapy is an alternative treatment for women with CAH or G1EC who desire fertility preservation. However, more prospective studies are needed for standard progestin regimen. Also, there still remains a risk of disease progression and recurrence. Therefore, close follow-up is important during treatment and after CR. In addition, a hysterectomy is recommended as a definitive treatment after completion of childbearing.
참고문헌 (28)
- Jemal A, "Global cancer statistics", CA Cancer J Clin, 61, pp.69~90 (2011)
- Gallup DG, "Adenocarcinoma of the endometrium in women 40 years of age or younger", Obstet Gynecol, 64, pp.417~420 (1984)
- Siegel R, "Cancer statistics, 2014", CA Cancer J Clin, 64, pp.9~29 (2014)
- Creasman WT, "Carcinoma of the corpus uteri", J Epidemiol Biostat, 6, pp.47~86 (2001)
- Barakat RR, "Gynecologic Oncology Group Study. Randomized doubleblind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study", J Clin Oncol, 24, pp.587~592 (2006)
- Duska LR, "Endometrial cancer in women 40 years old or younger", Gynecol Oncol, 83, pp.388~393 (2001)
- Gitsch G, "Endometrial cancer in premenopausal women 45 years and younger", Obstet Gynecol, 85, pp.504~508 (1995)
- Lee NK, "Prognostic factors for uterine cancer in reproductive-aged women", Obstet Gynecol, 109, pp.655~662 (2007)
- Tran BN, "Characteristics and outcome of endometrial carcinoma patients age 45 years and younger", Am J Clin Oncol, 23, pp.476~480 (2000)
- Soliman PT, "Risk factors for young premenopausal women with endometrial cancer", Obstet Gynecol, 105, pp.575~580 (2005)
- Simpson AN, "Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin", Gynecol Oncol, 133, pp.229~233 (2014)
- Crissman JD, "Endometrial carcinoma in women 40 years of age or younger", Obstet Gynecol, 57, pp.699~704 (1981)
- Lajer H, "Survival after stage IA endometrial cancer : can follow-up be altered? A prospective nationwide Danish survey", Acta Obstet Gynecol Scand, 91, pp.976~982 (2012)
- Silverberg SG, "Endometrial carcinoma in women under 40 years of age : comparison of cases in oral contraceptive users and non-users", Cancer, 39, pp.592~598 (1977)
- Dorais J, "Fertility-sparing management of endometrial adenocarcinoma", Obstet Gynecol Surv, 66, pp.443~451 (2011)
- Ramirez PT, "Hormonal therapy for the management of grade 1 endometrial adenocarcinoma : a literature review", Gynecol Oncol, 95, pp.133~138 (2004)
- Randall TC, "Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40", Obstet Gynecol, 90, pp.434~440 (1997)
- Gunderson CC, "Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1adenocarcinoma : a systematic review", Gynecol Oncol, 125, pp.477~482 (2012)
- Koskas M, "Progestin treatment of atypical hyperplasia and well-differentiated adenocarcinoma of the endometrium to preserve fertility", Anticancer Res, 32, pp.1037~1043 (2012)
- Kim YB, "Progestin alone as primary treatment of endometrial carcinoma in premenopausal women : report of seven cases and review of the literature", Cancer, 79, pp.320~327 (1997)
- Shirali E, "who conservatively treated with megestrol acetate", Arch Gynecol Obstet, 285, pp.791~795 (2012)
- Cade TJ, "Progestogen treatment options for early endometrial cancer", BJOG, 117, pp.879~884 (2010)
- Park JY, "Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002)", Eur J Cancer, 49, pp.868~874 (2013)
- Penner KR, "Predictors of resolution of complex atypical hyperplasia or grade 1 endometrial adenocarcinoma in premenopausal women treated with progestin therapy", Gynecol Oncol, 124, pp.542~548 (2012)
- Eftekhar Z, "Efficacy of megestrol acetate(megace)in the treatment of patients with early endometrial adenocarcinoma : our experiences with 21 patients", Int J Gynecol Cancer, 19, pp.249~252 (2009)
- Vereide AB, "Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ERbeta)in human endometrial hyperplasia", Gynecol Oncol, 101, pp.214~223 (2006)
- Gunderson CC, "Pathologic features associated with resolution of complex atypical hyperplasia and grade 1endometrial adenocarcinoma after progestin therapy", Gynecol Oncol, 132, pp.33~37 (2014)
- Gallos ID, "Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis", Am J Obstet Gynecol, 207, pp.266.e1~266. e12 (2012)